Transcatheter aortic valve replacement: The year in review 2017

This article is a continuation of our previously published annual reviews of transcatheter aortic valve replacement (TAVR). In 2017, TAVR further established a foothold in the management of intermediate risk patients with the publication of SURTAVI trial. Randomized trials also addressed the use of cerebral protection during TAVR and single versus dual antiplatelet therapy after TAVR. Newer generation valve systems continued to be studied for their efficacy and safety. This paper summarizes the major studies published in 2017.

[1]  K. Harjai,et al.  Suitability for Watchman Implantation in TAVR Patients with Atrial Fibrillation , 2018 .

[2]  V. Rigolin,et al.  2017 Focused Update for Management of Patients With Valvular Heart Disease: Summary of New Recommendations , 2018, Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease.

[3]  J. Leipsic,et al.  Self-Expanding Transcatheter Aortic Valve System for Symptomatic High-Risk Patients With Severe Aortic Stenosis. , 2017, Journal of the American College of Cardiology.

[4]  Jeroen J. Bax,et al.  Transcatheter Aortic Valve Replacement in Pure Native Aortic Valve Regurgitation. , 2017, Journal of the American College of Cardiology.

[5]  J. Rumsfeld,et al.  Transcatheter Aortic Valve Replacement in Patients With Aortic Stenosis and Mitral Regurgitation. , 2017, The Annals of thoracic surgery.

[6]  S. Windecker,et al.  Predictors of 1-Year Mortality After Transcatheter Aortic Valve Implantation in Patients With and Without Advanced Chronic Kidney Disease. , 2017, The American journal of cardiology.

[7]  Prashanth,et al.  Conscious Sedation Versus General Anesthesia for Transcatheter Aortic Valve Replacement , 2017 .

[8]  J. Leipsic,et al.  Association of Paravalvular Regurgitation With 1-Year Outcomes After Transcatheter Aortic Valve Replacement With the SAPIEN 3 Valve , 2017, JAMA cardiology.

[9]  L. Svensson,et al.  Impact of Coronary Artery Disease on 30‐Day and 1‐Year Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement: A Meta‐Analysis , 2017, Journal of the American Heart Association.

[10]  J. Harnek,et al.  Repositionable percutaneous aortic valve implantation with the LOTUS valve: 30-day and 1-year outcomes in 250 high-risk surgical patients. , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[11]  S. Windecker,et al.  Clinical Outcomes With a Repositionable Self-Expanding Transcatheter Aortic Valve Prosthesis: The International FORWARD Study. , 2017, Journal of the American College of Cardiology.

[12]  J. Leipsic,et al.  CT-Defined Prosthesis-Patient Mismatch Downgrades Frequency and Severity, and Demonstrates No Association With Adverse Outcomes After Transcatheter Aortic Valve Replacement. , 2017, JACC. Cardiovascular interventions.

[13]  I. Palacios,et al.  Frailty in Older Adults Undergoing Aortic Valve Replacement: The FRAILTY-AVR Study. , 2017, Journal of the American College of Cardiology.

[14]  Sean M. O'Brien,et al.  Transcatheter Versus Surgical Aortic Valve Replacement: Propensity-Matched Comparison. , 2017, Journal of the American College of Cardiology.

[15]  J. Harnek,et al.  Predictors of Paravalvular Regurgitation After Implantation of the Fully Repositionable and Retrievable Lotus Transcatheter Aortic Valve (from the REPRISE II Trial Extended Cohort). , 2017, The American journal of cardiology.

[16]  J. Webb,et al.  Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve: The ARTE (Aspirin Versus Aspirin + Clopidogrel Following Transcatheter Aortic Valve Implantation) Randomized Clinical Trial. , 2017, JACC. Cardiovascular interventions.

[17]  Eugene Blackstone,et al.  Procedural Experience for Transcatheter Aortic Valve Replacement and Relation to Outcomes: The STS/ACC TVT Registry. , 2017, Journal of the American College of Cardiology.

[18]  N. Weissman,et al.  Blood Pressure and Arterial Load After Transcatheter Aortic Valve Replacement for Aortic Stenosis , 2017, Circulation. Cardiovascular imaging.

[19]  Wen Cheng,et al.  Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study , 2017, The Lancet.

[20]  S. Kohsaka,et al.  Impact of the Clinical Frailty Scale on Outcomes After Transcatheter Aortic Valve Replacement , 2017, Circulation.

[21]  M. Deutsch,et al.  Safety and Efficacy of Transcatheter Aortic Valve Replacement in the Treatment of Pure Aortic Regurgitation in Native Valves and Failing Surgical Bioprostheses: Results From an International Registry Study. , 2017, JACC. Cardiovascular interventions.

[22]  J. Leipsic,et al.  Transcatheter Aortic Valve Implantation Within Degenerated Aortic Surgical Bioprostheses: PARTNER 2 Valve-in-Valve Registry. , 2017, Journal of the American College of Cardiology.

[23]  N. Moat,et al.  One-Year Outcomes of Transcatheter Aortic Valve Implantation Using the Direct Aortic Approach. , 2017, The Annals of thoracic surgery.

[24]  F. Spencer,et al.  Cerebral Embolic Protection Devices During Transcatheter Aortic Valve Implantation: Systematic Review and Meta-Analysis , 2017, Stroke.

[25]  D. Adams,et al.  One-Year Outcomes of Transcatheter Aortic Valve Replacement in Patients With End-Stage Renal Disease. , 2017, The Annals of thoracic surgery.

[26]  J. Leipsic,et al.  Computed Tomography-Based Oversizing Degrees and Incidence of Paravalvular Regurgitation of a New Generation Transcatheter Heart Valve. , 2017, JACC. Cardiovascular interventions.

[27]  D. Berman,et al.  A Highly Predictive Risk Model for Pacemaker Implantation After TAVR. , 2017, JACC. Cardiovascular imaging.

[28]  G. Richardt,et al.  Clinical Bioprosthetic Heart Valve Thrombosis After Transcatheter Aortic Valve Replacement: Incidence, Characteristics, and Treatment Outcomes. , 2017, JACC. Cardiovascular interventions.

[29]  P. Jüni,et al.  Comparison of procedural and clinical outcomes with Evolut R versus Medtronic CoreValve: a Swiss TAVI registry analysis. , 2017, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[30]  T. Walther,et al.  Matched Comparison of Self-Expanding Transcatheter Heart Valves for the Treatment of Failed Aortic Surgical Bioprosthesis: Insights From the Valve-in-Valve International Data Registry (VIVID) , 2017, Circulation. Cardiovascular interventions.

[31]  F. Neumann,et al.  SOURCE 3 Registry: Design and 30-Day Results of the European Postapproval Registry of the Latest Generation of the SAPIEN 3 Transcatheter Heart Valve. , 2017, Circulation.

[32]  Jeroen J. Bax,et al.  Outcomes in Transcatheter Aortic Valve Replacement for Bicuspid Versus Tricuspid Aortic Valve Stenosis. , 2017, Journal of the American College of Cardiology.

[33]  Andrew S. Mugglin,et al.  Surgical or Transcatheter Aortic‐Valve Replacement in Intermediate‐Risk Patients , 2017, The New England journal of medicine.

[34]  G. Deeb,et al.  Early Clinical Outcomes After Transcatheter Aortic Valve Replacement Using a Novel Self-Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Who Are Suboptimal for Surgery: Results of the Evolut R U.S. Study. , 2017, JACC. Cardiovascular interventions.

[35]  W. O’Neill,et al.  Transcaval Access and Closure for Transcatheter Aortic Valve Replacement: A Prospective Investigation. , 2017, Journal of the American College of Cardiology.

[36]  K. Harjai,et al.  Impact of Coronary Artery Disease Severity Assessed With the SYNTAX Score on Outcomes Following Transcatheter Aortic Valve Replacement , 2017, Journal of the American Heart Association.

[37]  G. Perlman,et al.  Electrocardiographic Predictors of Long‐Term Cardiac Pacing Dependency Following Transcatheter Aortic Valve Implantation , 2017, Journal of cardiovascular electrophysiology.

[38]  R. Virmani,et al.  Protection Against Cerebral Embolism During Transcatheter Aortic Valve Replacement. , 2017, Journal of the American College of Cardiology.

[39]  S. Nakatani,et al.  Clinical Outcomes and Bioprosthetic Valve Function After Transcatheter Aortic Valve Implantation Under Dual Antiplatelet Therapy vs. Aspirin Alone. , 2017, Circulation journal : official journal of the Japanese Circulation Society.

[40]  M. Zembala,et al.  Improvement of quality of life following transcatheter aortic valve implantation in the elderly: a multi-centre study based on the Polish national TAVI registry. , 2017, Kardiologia polska.

[41]  J. Popma,et al.  Balloon Post-Dilation Following Implantation of a Self-Expanding Transcatheter Aortic Valve Bioprosthesis. , 2017, JACC. Cardiovascular interventions.

[42]  K. Takagi,et al.  Pre-procedural dual antiplatelet therapy in patients undergoing transcatheter aortic valve implantation increases risk of bleeding , 2016, Heart.

[43]  M. Mack,et al.  Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. , 2016, The New England journal of medicine.

[44]  S. Blankenberg,et al.  Transcatheter valve-in-valve implantation versus redo surgical aortic valve replacement in patients with failed aortic bioprostheses. , 2017, Interactive cardiovascular and thoracic surgery.